p53 and cyclooxygenase-2 expression are directly associated with cyclin D1 expression in radical prostatectomy specimens of patients with hormone-naïve prostate cancer

Pathology and Oncology Research

Volumn 18, Issue 2, 2012, Pages 245-252

  Vlachostergios, Panagiotis J ^a   Karasavvidou, Foteini ^a   Patrikidou, Anna ^a   Voutsadakis, Ioannis A ^a   Kakkas, Grigorios ^a   Moutzouris, George ^a   Zintzaras, Elias ^b   Daliani, Danai D ^a   Melekos, Michael D ^a   Papandreou, Christos N ^a  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

Author keywords

Biochemical failure; Cyclin D1; Cyclooxygenase 2; p53; Prostate cancer; Radical prostatectomy

Indexed keywords

CYCLIN D1; CYCLOOXYGENASE 2; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53;

ARTICLE; CANCER PROGNOSIS; CANCER RELAPSE; CANCER STAGING; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE MARKER; EARLY CANCER; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION;

CYCLIN D1; CYCLOOXYGENASE 2; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863464455     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-011-9435-2     Document Type: Article

References (63)

1. Bostwick DG, Grignon DJ, Hammond ME et al (1999) Prognostic factors in prostate cancer. College of American pathologists consensus statement 1999. Arch Pathol Lab Med 124:995-1000
2. Brooks JD, Bova GS, Ewing CM et al (1996) An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res 56:3814-3822
3. Taylor D, Koch WM, Zahurak M et al (1999) Immunohistochemical detection of p53 protein accumulation in head and neck cancer: correlation with p53 gene alterations. Hum Pathol 30:1221-1225
4. Zha S, Yegnasubramanian V, Nelson WG et al (2004) Cyclooxygenases in cancer: progress and perspective. Cancer Lett 215:1-20
5. Pruthi RS, Derksen E, Gaston K (2003) Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review. J Urol 169:2352-2359
6. Gupta S, Srivastava M, Ahmad N et al (2000) Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42:73-78
7. Yoshimura R, Sano H, Masuda C et al (2000) Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 89:589-596
8. Lee LM, Pan CC, Cheng CJ et al (2001) Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Res 21:1291-1294
9. Uotila P, Valve E, Martikainen P et al (2001) Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res 29:23-28
10. Zang T, Sun F, Li Y (2001) Expression of COX-2 in prostatic cancer and benign prostatic hyperplasia. Zhonghua Wai Ke Za Zhi 39:702-703
11. Edwards J, Mukherjee R, Munro AF et al (2004) HER2 and COX2 expression in human prostate cancer. Eur J Cancer 40:50-55
12. Denkert C, Thoma A, Niesporek S et al (2007) Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia-association with increased expression of Polo-like kinase-1. Prostate 67:361-369
13. Shappell SB, Manning S, Boeglin WE et al (2001) Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia 3:287-303
14. Bartkova J, Lukas J, Strauss M et al (1995) Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 10:775-778
15. Chen Y, Martinez LA, LaCava M et al (1998) Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1. Oncogene 16:1913-1920
16. Gumbiner LM, Gumerlock PH, Mack PC et al (1999) Overexpression of cyclin D1 is rare in human prostate carcinoma. Prostate 38:40-45
17. Shiraishi T, Watanabe M, Muneyuki T et al (1998) A clinicopathological study of p53, p21 (WAF1/CIP1) and cyclin D1 expression in human prostate cancers. Urol Int 61:90-94
18. Osman I, Yee H, Taneja SS et al (2004) Neutral endopeptidase protein expression and prognosis in localized prostate cancer. Clin Cancer Res 10:4096-4100
19. Brehm A, Miska EA, McCance DJ et al (1998) Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 391:597-601
20. Guardavaccaro D, Corrente G, Covone F et al (2000) Arrest of G (1)-S progression by the p53-inducible gene PC3 is Rb dependent and relies on the inhibition of cyclin D1 transcription. Mol Cell Biol 20:1797-1815
21. Rocha S, Martin AM, Meek DW et al (2003) p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1. Mol Cell Biol 23:4713-4727
22. Agus DB, Cordon-Cardo C, Fox W et al (1999) Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst 91:1869-1876
23. Narayanan BA, Narayanan NK, Davis L et al (2006) RNA interference- mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation: modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptor. Mol Cancer Ther 5:1117-1125
24. Subbaramaiah K, Altorki N, Chung WJ et al (1999) Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 274:10911-10915
25. Han JA, Kim JI, Ongusaha PP et al (2002) P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis. EMBO J 21:5635-5644
26. Choi EM, Heo JI, Oh JY et al (2005) COX-2 regulates p53 activity and inhibits DNA damage-induced apoptosis. Biochem Biophys Res Commun 328:1107-1112
27. Bauer JJ, Sesterhenn IA, Mostofi KF et al (1995) p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin Cancer Res 1:1295-1300
28. Shurbaji MS, Kalbfleisch JH, Thurmond TS (1995) Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol 26:106-109
29. Bauer JJ, Sesterhenn IA, Mostofi FK et al (1996) Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 156:1511-1516
30. Moul JW, Bettencourt MC, Sesterhenn IA et al (1996) Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery 120:159-166
31. Theodorescu D, Broder SR, Boyd JC et al (1997) P53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 158:131-137
32. Brewster SF, Oxley JD, Trivella M et al (1999) Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol 161:1238-1243
33. Osman I, Drobnjak M, Fazzari M et al (1999) Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin Cancer Res 5:2082-2088
34. Leibovich BC, Cheng L, Weaver AL et al (2000) Outcome prediction with p53 immunostaining after radical prostatectomy in patients with locally advanced prostate cancer. J Urol 163:1756-1760
35. Deliveliotis C, Skolarikos A, Karayannis A et al (2003) The prognostic value of p53 and DNA ploidy following radical prostatectomy. World J Urol 21:171-176
36. Schlomm T, Iwers L, Kirstein P et al (2008) Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol 21:1371-1378
37. Oxley JD, Winkler MH, Parry K et al (2002) P53 and bcl-2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy. BJU Int 89:27-32
38. Revelos K, Petraki C, Gregorakis A et al (2005) Immunohistochemical expression of Bcl2 is an independent predictor of time-tobiochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. Anticancer Res 25:3123-3133
39. Yang G, Stapleton AM, Wheeler TM et al (1996) Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. Clin Cancer Res 2:399-401
40. Stapleton AM, Zbell P, Kattan MWet al (1998) Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer 82:168-175
41. Quinn DI, Henshall SM, Head DR et al (2000) Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res 60:1585-1594
42. Inoue T, Segawa T, Shiraishi T et al (2005) Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology 66:332-337
43. Wu TT, Hsu YS, Wang JS et al (2003) The role of p53, bcl-2 and E-cadherin expression in predicting biochemical relapse for organ confined prostate cancer in Taiwan. J Urol 170:78-81
44. Goto T, Nguyen BP, Nakano M et al (2008) Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population. Urology 72:167-171
45. Nariculam J, Freeman A, Bott S et al (2009) Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors. Asian J Androl 11:109-118
46. Krupski T, Petroni GR, Frierson HF Jr et al (2000) Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate. Urology 55:743-749
47. Leibovich BC, Cheng L, Weaver AL et al (2000) Outcome prediction with p53 immunostaining after radical prostatectomy in patients with locally advanced prostate cancer. J Urol 163:1756-1760
48. Visakorpi T, Kallioniemi OP, Heikkinen A et al (1992) Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84:883-887
49. Deliveliotis C, Skolarikos A, Karayannis A et al (2003) The prognostic value of p53 and DNA ploidy following radical prostatectomy. World J Urol 21:171-176
50. Kirschenbaum A, Klausner AP, Lee R et al (2000) Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology 56:671-676
51. Zha S, Gage WR, Sauvageot J et al (2001) Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 61:8617-8623
52. Wang W, Bergh A, Damber JE (2005) Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 11:3250-3256
53. Dassesse T, de Leval X, de Leval L et al (2006) Activation of the thromboxane A2 pathway in human prostate cancer correlates with tumor Gleason score and pathologic stage. Eur Urol 50:1021-1031
54. Di Lorenzo G, De Placido S, Autorino R et al (2005) Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease. Prostate Cancer Prostatic Dis 8:54-59
55. Rubio J, Ramos D, López-Guerrero JA et al (2005) Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Eur Urol 48:745-751
56. Rao DS, Gui D, Koski ME et al (2006) An inverse relation between COX-2 and E-cadherin expression correlates with aggressive histologic features in prostate cancer. Appl Immunohistochem Mol Morphol 14:375-383
57. Cohen BL, Gomez P, Omori Y et al (2006) Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence. Int J Cancer 119:1082-1087
58. Bin W, He W, Feng Z, et al (2009) Prognostic relevance of cyclooxygenase-2 (COX-2) expression in Chinese patients with prostate cancer. Acta Histochem (in press). doi:10.1016/j.acthis.2009.09.004
59. Comstock CE, Revelo MP, Buncher CR et al (2007) Impact of differential cyclin D1 expression and localisation in prostate cancer. Br J Cancer 96:970-979
60. Kallakury BV, Sheehan CE, Ambros RA et al (1997) The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma. Cancer 80:753-763
61. Drobnjak M, Osman I, Scher HI et al (2000) Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res 6:1891-1895
62. Aaltomaa S, Kärjä V, Lipponen P et al (2006) Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy. Anticancer Res 26:4873-4878
63. Gannon PO, Koumakpayi IH, Le Page C et al (2008) Ebp1 expression in benign and malignant prostate. Cancer Cell Int 8:18-28